摘要
目的:回顾性分析18F-FDGPET显像在血清肿瘤标志物异常而其他影像学检查阴性或不能提供明确的诊断的患者中的应用价值。材料和方法:血清肿瘤标志物升高的患者21例,其他影像学检查结果为阴性,或不能得出明确结论。所有患者均接受全身18F-FDGPET显像,血清肿瘤标志物检查于18F-FDGPET显像前2周内进行。每一位患者的最终诊断均得自于手术/活检的病理学结论或1年以上的随访的基础之上。结果:18F-FDGPET评价血清肿瘤标志物升高患者的敏感性为92.3%(12/13),特异性为62.5%(5/8),准确性为81.0%(17/21),阳性预期值为80%(12/15),阴性预期值为83.3%(5/6)。结论:对于不明原因的血清肿瘤标志物升高的患者,18F-FDGPET全身显像具有重要的意义,将有可能改变对这些患者进一步的治疗措施。
To evaluate retrospectively the impact of [ 18 F] fluorodeoxyglucose positron emission tomog-raphy( 18 F-FDG PET)on the detection of patients with elevated tumor markers levels but negative or equivocal other imaging modality results.Materials and Methods:Whole-body 18 F-FDG PET was performed in21patients with asymptomatic tumor marker increase but negative or equivocal other imaging modality results.A blood sample was drawn in each case for marker assay14days or less before the day performing the 18 F-FDG PET.The final diagnosis was established by operation/biopsy histopathological findings or clinical follow-up for more than1year.Results:The diagnostic sensitivity and specificity of18F-FDG PET in patients with asymptomatically elevated tumor markers were92.3%(12/13)and62.5%(5/8),accuracy81.0%(17/21),positive and negative predictive value80%(12/15)and83.3%(5/6).Conclusions: 18 F-FDG PET is a useful technique for asymptomatically elevated tu-mor markers levels and has an important clinical impact on the management of these patients.
出处
《中国医学计算机成像杂志》
CSCD
2005年第3期205-207,共3页
Chinese Computed Medical Imaging
